Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Aeolus Pharmaceuticals, Inc.
NIH CounterACT Program Begins Studies of Aeolus Pharmaceuticals’ AEOL 10150 as a Countermeasure to Sulfur Mustard Gas Exposure
February 27th, 2009
Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board:AOLS) announced the initiation of the first of a series of studies of AEOL 10150 as a countermeasure to mustard gas exposure. The studies, funded by the National Institutes for Health’s CounterACT program, have been designed to test the efficacy of AEOL 10150 as a treatment for damage to the skin, lungs and eyes due to exposure to sulfur mustard gas and to examine potential effective doses, duration of delivery and the window of opportunity for treatment after exposure. The new studies will be conducted using “whole” sulfur mustard gas and build on results from previous studies using CEES, an analog of mustard gas, which...
Source: Health Business Week (2009-02-27)
|
